Synthetic Biologics Inc (TOVX) stock has reached a new 52-week low, trading at $1.21. This latest price point marks a significant downturn for the company, which has seen its stock value decrease by -91.13% over the past year. According to InvestingPro analysis, the company's financial health score stands at 1.71 (Weak), with EBITDA at -$20.06M for the last twelve months. Investors are closely monitoring the biopharmaceutical company, known for its focus on developing therapies for gut microbiome-related diseases, as it navigates through a challenging period marked by this notable decline in its stock price. The 52-week low serves as a critical indicator for the market, reflecting investor sentiment and the company's performance in a competitive industry. InvestingPro data reveals that while the company maintains a healthy current ratio of 2.67 and holds more cash than debt, it's currently experiencing rapid cash burn. Subscribers can access 13 additional ProTips and a comprehensive Pro Research Report for deeper insights into TOVX's financial position.
In other recent news, Theriva Biologics has made significant progress in several areas. The company's leading candidate, VCN-01, is being developed for the treatment of metastatic pancreatic adenocarcinoma. The U.S. Food and Drug Administration (FDA) has recommended a separate Phase 3 study for VCN-01, affirming the proposed design without additional standard-of-care chemotherapy. This decision comes as the ongoing VIRAGE Phase 2b study, evaluating VCN-01 as a first-line therapy for PDAC patients, enters its final patient follow-up phase.
VCN-01 has also gained EU orphan drug status for retinoblastoma treatment, following a similar designation by the FDA. The company has reported positive outcomes from a Phase 1 trial assessing VCN-01's safety and activity in this context. Furthermore, Theriva Biologics has seen progress in the clinical trial of its drug SYN-004, designed to prevent acute graft-versus-host-disease in recipients of allogeneic hematopoietic cell transplants.
Additionally, Theriva Biologics has announced a reverse stock split of its common stock at a 1-for-25 ratio. The FDA has also granted VCN-01 both Rare Pediatric Drug Designation and Fast Track Designation for treating metastatic pancreatic adenocarcinoma in combination with chemotherapy drugs. These are all recent developments in Theriva Biologics' ongoing commitment to address unmet medical needs in oncology.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.